091-18820 Re

For Internal Use Only
Sec File No. 9-

26 PH 3: 43

SEC / MR

Submit 1 Original and 9 Copies

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0504

Expires: August 31, 2013 Estimated average burden hours per response. 3.60

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New SEC

Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange processing

	Derivative Securities Product Pursuant to Rule 196-4(e) Under the Securities	Section	
	READ ALL INSTRUCTIONS PRIOR TO COMPLETIN	G FORM JUN 26 2015	
Part I	Initial Listing Report	Wasnington DC	
1.	Name of Self-Regulatory Organization Listing New Derivative Securities Product: Objects Stock Evolution 199		
2.	Chicago Stock Exchange, Inc. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker	dealer, corporation, etc.):	1_
	Trust		
3.	Class of New Derivative Securities Product: Ownership of the Trust		
4.	Name of Underlying Instrument:		M
	ProShares UltraPro Short Nasdaq Biotechnology	15000887	
5.	If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow Narrow-Based	-Based:	
6.	Ticker Symbol(s) of New Derivative Securities Product:	3]
August .	ZBIO		
7.	Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:		
	Various		-
8.	Settlement Methodology of New Derivative Securities Product: See Prospectus		
9,	Position Limits of New Derivative Securities Product (if applicable):		
	See Prospectus		
- Part II	Part II Execution		
	The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new		
	derivative securities product according to its relevant trading rules, procedures,	surveillance programs and listing	
*	standards.		
Name o	of Official Responsible for Form:		7
	Michael J. Cardin		1
::Title:	Director		7
	Member Regulation Department		
Telepho	one Number:		4
L	312-663-2204 Act	Securities Exchange Act of 1934	
Manual Signature of Official Responsible for Form			7
Date:	Rule	19b-4(e)	Ŧ
Date.	June 24, 2015 Public Available	MIN: JUN 2 6 2015	
550 244	C 2440 (6.01)		



SEC Mail Processing Section

JUN 26 2015

Washington DC 404

June 24, 2015

By UPS

Ms. Gayle S. Jackson Division of Trading and Markets Securities and Exchange Commission 100 F Street NE - Stop 7010 Washington, DC 20549

Form 19b-4(e) for exchange traded product Re:

Dear Ms. Jackson:

Pursuant to Rule 19b-4(e) of the Securities Exchange Act of 1934, I enclose for filing an original and four copies of the Form 19b-4(e) relating to the following exchange traded product:

ZBIO	ProShares UltraPro Short Nasdaq Biotechnology
UBIO	ProShares UltraPro Nasdaq Biotechnology

If you have any questions about this filing, please contact the undersigned at (312) 663-2204 or Kevin Curtin at (312) 663-2252.

Sincerely,

Director

Member Regulation Department

Enclosures

Act Securities Exchange Act of 1934

Section 19b-4 Rule 19b-4(e)

Public

JUN 2 6 2015 Availability: